Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review highlights the potential of peptide-based PROTACs (pPROTACs) in expanding the target range of protein degraders beyond small-molecule limitations, particularly for undruggable proteins, by utilizing advances in design, conjugation, and bioPROTAC technology.

In this study, researchers developed de novo designed hetero-bifunctional proteins as an alternative approach for targeted protein degradation, successfully targeting BCL-xL for degradation in cells and inducing apoptosis, which may expand the range of addressable E3 ligases and disease targets.